NovMetaPharma Co (XKRX:229500) Revenue : ₩45.32 Mil (TTM As of Dec. 2024)

NovMetaPharma Co Revenue Chart

NovMetaPharma Co Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Revenue		Get a 7-Day Free Trial					44.30	74.48	31.48	13.85	45.32

NovMetaPharma Co Semi-Annual Data
	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Revenue	Get a 7-Day Free Trial					44.30	74.48	31.48	13.85	45.32

Competitive Comparison of NovMetaPharma Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, NovMetaPharma Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovMetaPharma Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NovMetaPharma Co's Revenue distribution charts can be found below:

* The bar in red indicates where NovMetaPharma Co's Revenue falls into.

NovMetaPharma Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was ₩45.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovMetaPharma Co  (XKRX:229500) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

NovMetaPharma Co Revenue Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NovMetaPharma Co Business Description